Additionally, male patients with a female partner of reproductive potential should use effective contraception during methotrexate therapy and for at least 3 months after therapy due to the risk of male-mediated teratogenicity.
Zousätzlech männlech Patienten mat engem weiblechen Partner vu reproduktive Potenzial sollten effektiv Ënnerdréckung bei der Therapie an zumindest 6 Méint no der Therapie wéinst der Gefor vu männlech vermittelter Teratogenitéit benotzen.